75 related articles for article (PubMed ID: 20601449)
1. The subtype-specific effects of droperidol on action potential duration in cellular and computational models of long QT syndrome.
Schwoerer AP; Kebernik J; Ehmke H; Friederich P
Anesth Analg; 2010 Sep; 111(3):638-46. PubMed ID: 20601449
[TBL] [Abstract][Full Text] [Related]
2. Bupivacaine destabilizes action potential duration in cellular and computational models of long QT syndrome 1.
Schwoerer AP; Zenouzi R; Ehmke H; Friederich P
Anesth Analg; 2011 Dec; 113(6):1365-73. PubMed ID: 22003215
[TBL] [Abstract][Full Text] [Related]
3. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle.
Jost N; Virág L; Bitay M; Takács J; Lengyel C; Biliczki P; Nagy Z; Bogáts G; Lathrop DA; Papp JG; Varró A
Circulation; 2005 Sep; 112(10):1392-9. PubMed ID: 16129791
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiologic effects of nicorandil on the guinea pig long QT1 syndrome model.
Yang Z; Shi G; Li C; Wang H; Liu K; Liu Y
J Cardiovasc Electrophysiol; 2004 Jul; 15(7):815-20. PubMed ID: 15250869
[TBL] [Abstract][Full Text] [Related]
5. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
Aiba T; Shimizu W; Inagaki M; Noda T; Miyoshi S; Ding WG; Zankov DP; Toyoda F; Matsuura H; Horie M; Sunagawa K
J Am Coll Cardiol; 2005 Jan; 45(2):300-7. PubMed ID: 15653031
[TBL] [Abstract][Full Text] [Related]
6. The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential.
Gao Z; Milnes JT; Choisy SC; Leach MJ; Hancox JC; James AF
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1088-96. PubMed ID: 16445575
[TBL] [Abstract][Full Text] [Related]
7. Choline-modulated arsenic trioxide-induced prolongation of cardiac repolarization in Guinea pig.
Sun HL; Chu WF; Dong DL; Liu Y; Bai YL; Wang XH; Zhou J; Yang BF
Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):381-8. PubMed ID: 16623862
[TBL] [Abstract][Full Text] [Related]
8. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve.
Vormberge T; Hoffmann M; Himmel H
J Pharmacol Toxicol Methods; 2006; 54(2):130-40. PubMed ID: 16757186
[TBL] [Abstract][Full Text] [Related]
9. A molecular basis for the therapy of the long QT syndrome.
Priori SG; Napolitano C; Schwartz PJ
Arch Mal Coeur Vaiss; 1996 Sep; 89(9):1185-7. PubMed ID: 8952843
[TBL] [Abstract][Full Text] [Related]
10. Re-entrant cardiac arrhythmias in computational models of long QT myocardium.
Clayton RH; Bailey A; Biktashev VN; Holden AV
J Theor Biol; 2001 Jan; 208(2):215-25. PubMed ID: 11162065
[TBL] [Abstract][Full Text] [Related]
11. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
[TBL] [Abstract][Full Text] [Related]
12. Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation.
Takahara A; Sugiyama A; Hashimoto K
Br J Pharmacol; 2005 Oct; 146(4):561-7. PubMed ID: 16056235
[TBL] [Abstract][Full Text] [Related]
13. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
14. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current.
Drolet B; Zhang S; Deschênes D; Rail J; Nadeau S; Zhou Z; January CT; Turgeon J
J Cardiovasc Electrophysiol; 1999 Dec; 10(12):1597-604. PubMed ID: 10636190
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction between DPI 201-106, a drug that mimics congenital long QT syndrome, and sevoflurane on the guinea-pig cardiac action potential.
Kang J; Chen XL; Reynolds WP; Rampe D
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1313-6. PubMed ID: 17892500
[TBL] [Abstract][Full Text] [Related]
16. Cellular mechanism of the QT prolongation induced by sulpiride.
Lee HA; Kim KS; Park SJ; Kim EJ
Int J Toxicol; 2009; 28(3):207-12. PubMed ID: 19546258
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide.
Hanada E; Ohtani H; Hirota M; Uemura N; Nakaya H; Kotaki H; Sato H; Yamada Y; Iga T
J Pharm Pharmacol; 2003 Jul; 55(7):995-1002. PubMed ID: 12906757
[TBL] [Abstract][Full Text] [Related]
18. Action potential changes associated with a slowed inactivation of cardiac voltage-gated sodium channels by KB130015.
Macianskiene R; Bito V; Raeymaekers L; Brandts B; Sipido KR; Mubagwa K
Br J Pharmacol; 2003 Aug; 139(8):1469-79. PubMed ID: 12922934
[TBL] [Abstract][Full Text] [Related]
19. A computational analysis of the effect of sevoflurane in a human ventricular cell model of long QT syndrome: Importance of repolarization reserve in the QT-prolonging effect of sevoflurane.
Kojima A; Fukushima Y; Itoh H; Imoto K; Matsuura H
Eur J Pharmacol; 2020 Sep; 883():173378. PubMed ID: 32710951
[TBL] [Abstract][Full Text] [Related]
20. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome.
Gallacher DJ; Van de Water A; van der Linde H; Hermans AN; Lu HR; Towart R; Volders PG
Cardiovasc Res; 2007 Nov; 76(2):247-56. PubMed ID: 17669388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
